Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

December 2017

Keytruda and Opdivo Prior Authorization Policies Updated

Harvard Pilgrim has updated our prior authorization policies for the cancer medications Keytruda and Opdivo to include additional covered indications and updated criteria, effective immediately.


Harvard Pilgrim now covers Keytruda for the treatment of the following additional indications, when all applicable criteria are met:

  • Malignant pleural mesothelioma
  • Merkel cell carcinoma
  • Gastric carcinoma

In addition, prior treatment with a fluoropyrimidine, oxaliplatin, and irinotecan is no longer required for Keytruda to be covered for the treatment of microsatellite instability-high colorectal cancer.


Harvard Pilgrim now reimburses the use of Opdivo for the treatment of the following additional indications, when all applicable criteria are met:

  • Microsatellite instability-high colorectal cancer
  • Malignant pleural mesothelioma
  • Hepatocellular carcinoma

Requesting prior authorization

As a reminder, CVS Health–NovoLogix oversees our prior authorization program for medical drugs to optimize treatment outcomes and promote the safe and cost-effective use of these medications. To request authorization for Keytruda and Opdivo, please contact CVS Health–NovoLogix via phone (844-387-1435) or fax (844-851-0882).

For complete information, please refer to our updated Keytruda Medical Review Criteria and Opdivo Medical Review Criteria.

Email this article to a colleague   

Network Matters Archives

Download printer-friendly version


New Monthly Publication Date for Network Matters

New Policy: Maximum Dosages for Medical Drugs

Webinar for Genetic Testing Authorization for Medicare Members

New Medicare Beneficiary Identifier Coming in 2018

Methadone Maintenance Benefit Change in Massachusetts

Study Suggests Breastfed Babies Are Less Likely to Have Eczema as Teens


Changes to Premium Formulary for 2018

New Prior Authorization Policy for Radicava

Keytruda and Opdivo Prior Authorization Policies Updated

Depression Screening and Treatment


Keep Panel Status and Demographic Information Up to Date


Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Senior Vice President, Network Strategy

Annmarie Dadoly,

Joseph O'Riordan,

Kristin Edmonston,
Production Coordinator